Eli Lilly's Orforglipron Achieves Significant Weight Loss in Late-Stage Trial

Eli Lilly's investigational oral weight-loss medication, orforglipron, has achieved significant results in a late-stage clinical trial involving patients with obesity and Type 2 diabetes. The highest dose of the once-daily pill led to an average weight reduction of 10.5%, or approximately 22.9 pounds, over a 72-week period. In contrast, participants receiving a placebo experienced a 2.2% weight loss. Additionally, orforglipron improved blood sugar control, with 75% of patients on the highest dose achieving hemoglobin A1c levels of 6.5% or below. The trial's safety profile was consistent with other GLP-1 receptor agonists, with gastrointestinal side effects such as nausea and vomiting being the most common. Eli Lilly plans to submit orforglipron for regulatory approval by the end of the year, aiming for a global launch in the following year. If approved, orforglipron would offer a needle-free alternative in the weight-loss and diabetes treatment market, potentially enhancing accessibility and addressing current supply challenges associated with injectable therapies.